KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate

Key Takeaways Kodiak Sciences shares jumped 75% after GLOW2 met its primary endpoint with strong efficacy data.KOD's Zenkuda showed 62.5% DRSS improvement vs. 3.3% for sham at week 48 in the phase III study.Zenkuda cut the risk of severe complications by 85% and showed consistent efficacy across GLP-1 users.Shares of Kodiak Sciences (KOD) surged 75% on March 26 after the company announced positive top-line results from the phase III GLOW2 study evaluating Zenkuda (tarcocimab tedromer) for the treatment of p ...